- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01239134
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)
Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
TRX518-001 is an open label, non-randomized single group assignment, Phase 1 single dose escalation study in adults with biopsy proven unresectable Stage III or Stage IV melanoma or other solid tumor malignancies.
Part A: The study objectives are to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of TRX518 and to define the maximum tolerated dose at which there are tolerable side effects and/or maximum PK/PD parameter changes.
Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a subject is enrolled and cohorts will be dosed consecutively by ascending dose. Part A has been completed.
Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy with objectives including characterization of the safety, tolerability, and pharmacokinetics, as well as, evaluate for evidence of anti-tumor activity and assess TRX518 immunogenicity.
Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Study Overview
Status
Intervention / Treatment
Detailed Description
The following visits are required:
Part A:
- Screening visit: 1 to 2 appointments will be conducted to determine eligibility. All or most requirements can be determined from the patient's medical records.
- Baseline visit: within 7 days of the planned study dosing day a baseline physical exam, blood tests and electrocardiogram will be obtained.
- Dosing visit: 1 outpatient visit where TRX518 will be given IV over 1 hour followed by 4 hours of observation and some repeat blood tests.
- Follow up visits: 5 outpatient visits following dosing at 1, 8 and 15 days and 3, 6, 12, and 18 weeks post dosing
- Long term follow-up: 4 brief assessments by medical record review and/or telephone contact at 6, 12, 18, and 24 months post dosing.
- The core study duration is 18 weeks. The follow-up study duration is 24 months.
Parts B & C:
- Screening/Baseline visit: 1 appointment will be conducted to perform testing and evaluations for eligibility within 28 days of the first dosing day.
- Dosing Visits: Each subject will receive IV doses of TRX518 once every other week (e.g., D1 and D15) in 28-day cycles
- Follow up visits: When a patient stops treatment, they will enter the Follow-up Period and have an End of Treatment study visit approximately 30 days after the last dose of study drug. Subsequently, patients will have long-term follow-up approximately every 12 weeks until death or lost to follow up.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Immunotherapeutics Core / Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Parts B & C):
- 18 years or older
- Histologically confirmed unresectable Stage III or Stage IV malignant melanoma, or other solid tumor malignancies
- Failed to respond to or relapsed following standard treatment, declined or was not eligible for standard treatment.
- Expected survival of at least 12 weeks.
- Eastern Cooperative Oncology Group performance status score of 0 or 1 is required.
- Evidence of adequate organ function by standard laboratory tests.
Exclusion Criteria (Parts B & C):
- Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 35 days prior to dosing.
- Ocular melanoma which has not metastasized or presence of a non-solid tumor.
- A history of any major surgery within 4 weeks prior to dosing.
- Any history of antitumor therapy completed within 28 days prior to dosing.
- Subjects with active autoimmune disease or history of known or suspected autoimmune disease, with the exception of subjects with isolated vitiligo, resolved childhood asthma/atopy, psoriasis not requiring systemic treatment and controlled thyroid disorders.
- Clinically significant heart disease, defined as NYHA Class III or IV.
- Any significant systemic infection requiring IV antibiotics.
- Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCAb) unless HCV RNA undetected/negative.
- Treatment with any other anti-human GITR monoclonal antibody (mAb) or immunomodulatory therapy 42 days prior to dosing (30 days for Interleukin-2 & Interferon-α, 7 days for Topical Imiquimod).
- Adverse events from prior anti-cancer therapy that have not resolved to grade ≤1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy.
- Use of any investigational drugs within 30 days prior to dosing.
- Any condition that requires or is likely to require treatment with pharmacologic doses of systemic corticosteroids. Subjects are permitted to receive physiologic replacement of corticosteroid therapy (≤ 10 mg prednisone daily).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRX518
|
Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Adverse Events
Time Frame: through 30 days post last dose
|
Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal
|
through 30 days post last dose
|
Part A: TRX518 peak concentration (Cmax)
Time Frame: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Part A: Time to peak concentration (Tmax)
Time Frame: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Part A: Area under the curve (AUC)
Time Frame: various timepoints through 1 week post dose
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
various timepoints through 1 week post dose
|
Part A: Define a maximum single dose at which there are tolerable side effects and/or maximum PK/PcD parameter changes
Time Frame: End of Cycle 1 (Day 28)
|
End of Cycle 1 (Day 28)
|
|
Parts B and C: Adverse Events
Time Frame: through 30 days post dose
|
Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal
|
through 30 days post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: Evaluate the effect of TRX518 on lymphoid cell subset number and function
Time Frame: At baseline and at various timepoints up to 6 weeks post dose
|
At baseline and at various timepoints up to 6 weeks post dose
|
|
Part A: Assess TRX518 immunogenicity
Time Frame: At baseline and at various timepoints up to 18 weeks post dose
|
At baseline and at various timepoints up to 18 weeks post dose
|
|
Part A: Evaluate the effect of TRX518 on long-term safety measuring vital signs, tumor status, adverse events
Time Frame: At Months 6, 12, 18 and 24
|
At Months 6, 12, 18 and 24
|
|
Parts B & C: TRX518 peak concentration (Cmax)
Time Frame: At each study visit from baseline up to end of treatment visit
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
At each study visit from baseline up to end of treatment visit
|
Parts B & C: Time to peak concentration (Tmax)
Time Frame: At each study visit from baseline up to end of treatment visit
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
At each study visit from baseline up to end of treatment visit
|
Parts B & C: Area under the curve (AUC)
Time Frame: At each study visit from baseline up to end of treatment visit
|
Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518
|
At each study visit from baseline up to end of treatment visit
|
Parts B & C: Evaluate multi-dose TRX18 monotherapy for any evidence of antitumor activity (objective response rate, [ORR] progression free survival [PFS], duration of response and overall survival [OS]; RECIST v1.1 will be utilized
Time Frame: Every 8 weeks while on study treatment and every 12 weeks for survival until death or lost to follow up.
|
objective response rate [ORR], progression free survival [PFS], duration of response [DoR] and overall survival [OS]); RECIST v1.1 criteria will be utilized
|
Every 8 weeks while on study treatment and every 12 weeks for survival until death or lost to follow up.
|
Parts B & C: Evaluate the effect of multi-dose TRX518 monotherapy on lymphoid cell subset number and function
Time Frame: At baseline and at various timepoints up to end of treatment visit
|
At baseline and at various timepoints up to end of treatment visit
|
|
Parts B & C: Assess TRX518 immunogenicity
Time Frame: At baseline and at various timepoints up to end of treatment visit
|
At baseline and at various timepoints up to end of treatment visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Principle Investigator: Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRX518-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
-
Bristol-Myers SquibbCompletedUnresectable Stage III or IV Malignant MelanomaUnited States, Peru, Norway, Italy, Sweden, Denmark, Israel
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
Celldex TherapeuticsTerminatedUnresectable Stage III or Stage IV MelanomaUnited States
-
CuraGen CorporationCompletedUnresectable Stage III or Stage IV MelanomaUnited States
-
National Cancer Institute (NCI)WithdrawnMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative... and other conditions
-
Elizabeth Buchbinder, MDGenentech, Inc.RecruitingStage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous MelanomaUnited States
-
Bristol-Myers SquibbNo longer availableStage III (Unresectable) or Stage IV Advanced MelanomaUnited States, Canada, Argentina, Colombia, Peru, Brazil
-
University Health Network, TorontoCompletedPreviously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV MelanomaCanada
-
National Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8United States
-
St. Louis UniversityCompletedMelanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III MelanomaUnited States
Clinical Trials on TRX518
-
Leap Therapeutics, Inc.Completed
-
Leap Therapeutics, Inc.Pfizer; Merck KGaA, Darmstadt, GermanyTerminatedSolid Tumors | Advanced Triple Negative Breast Cancer | Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer | Advanced Metastatic Castration-Resistant Prostate Cancer | Advanced Platinum-Resistant Ovarian CancerUnited States